27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Bernard J. Zovighian, insider at Edwards Lifesciences

Bernard J. Zovighian Insider Information

Bernard J. Zovighian has been corporate vice president since January 2016 and is currently responsible for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business. The patients impacted by mitral and tricuspid heart valve diseases suffer from debilitating conditions that, at best, severely diminish their quality of life, and at worst, are life threatening. As the leader for Edwards TMTT since 2018, Zovighian has established an organization focused on developing and delivering a portfolio of therapies designed to change the standard of care for mitral and tricuspid patients. Zovighian joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Structural Heart business, later serving as corporate vice president from 2016-2017. During his leadership of Edwards’ surgical therapies, the company received regulatory approval and launched two important breakthrough therapies globally, as well as completed an acquisition of a pioneering beating-heart repair for degenerative mitral regurgitation. Prior to joining Edwards, Zovighian held a variety of roles with increasing levels of responsibility at Johnson & Johnson (J&J) for nearly 20 years, including worldwide president of Advanced Sterilization Products, president of JJMP – J&J’s medical technology businesses in Canada – and Cordis. Zovighian has extensive senior leadership experience in the medical technology industry in Europe and North America where he has led the development and adoption of disruptive technology that has elevated the standard of care. He received a master’s degree in biomedical engineering from University of Marseille and an executive MBA from Euromed Management, both in France.

What is Bernard J. Zovighian's net worth?

The estimated net worth of Bernard J. Zovighian is at least $2.16 million as of August 5th, 2022. Zovighian owns 21,247 shares of Edwards Lifesciences stock worth more than $2,155,296 as of August 10th. This net worth approximation does not reflect any other investments that Zovighian may own. Learn More about Bernard J. Zovighian's net worth.

How do I contact Bernard J. Zovighian?

The corporate mailing address for Zovighian and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected] Learn More on Bernard J. Zovighian's contact information.

Has Bernard J. Zovighian been buying or selling shares of Edwards Lifesciences?

During the last ninety days, Bernard J. Zovighian has sold $498,708.26 of Edwards Lifesciences stock. Most recently, Bernard J. Zovighian sold 4,811 shares of the business's stock in a transaction on Friday, August 5th. The shares were sold at an average price of $103.66, for a transaction totalling $498,708.26. Following the completion of the sale, the vice president now directly owns 21,247 shares of the company's stock, valued at $2,202,464.02. Learn More on Bernard J. Zovighian's trading history.

Who are Edwards Lifesciences' active insiders?

Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.

Are insiders buying or selling shares of Edwards Lifesciences?

In the last year, Edwards Lifesciences insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $168,345.00. In the last year, insiders at the medical research company sold shares 46 times. They sold a total of 668,116 shares worth more than $73,643,209.19. The most recent insider tranaction occured on August, 5th when VP Bernard J Zovighian sold 4,811 shares worth more than $498,708.26. Insiders at Edwards Lifesciences own 1.3 % of the company. Learn More about insider trades at Edwards Lifesciences.

Information on this page was last updated on 8/5/2022.

Bernard J. Zovighian Insider Trading History at Edwards Lifesciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2022Sell4,811$103.66$498,708.2621,247View SEC Filing Icon  
5/31/2022Sell9,000$100.83$907,470.0030,816View SEC Filing Icon  
5/24/2022Sell4,809$95.52$459,355.6839,816View SEC Filing Icon  
4/27/2017Sell18,050$109.21$1,971,240.50View SEC Filing Icon  
See Full Table

Bernard J. Zovighian Buying and Selling Activity at Edwards Lifesciences

This chart shows Bernard J Zovighian's buying and selling at Edwards Lifesciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edwards Lifesciences Company Overview

Edwards Lifesciences logo
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $103.80
Low: $102.44
High: $103.97

50 Day Range

MA: $97.45
Low: $86.50
High: $107.29

2 Week Range

Now: $103.80
Low: $85.58
High: $131.73

Volume

81,476 shs

Average Volume

2,720,079 shs

Market Capitalization

$64.35 billion

P/E Ratio

44.94

Dividend Yield

N/A

Beta

1.12
Average 126% gains – NO losers!?  
An epic crash is all but inevitable, but these dark times can offer staggering opportunities.

Today, Dr. Martin Weiss reveals "Crash Profit Trades" that could have produced average gains of 126% even when stocks tumbled.

All with NO losing trades!

Click Here to Discover the Secret.
>>>